1Wang M, Zhou Y, Zhang L, et al. Use of bortezomib in B - cell non - Hodgkin' s lymphoma. Expert Rev Anticancer Ther,2006(7) :983.
2Orlowski R Z, Voorhees P M, Garcia R A, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxombicin in patients with advanced hematologic malignancies. Blood, 2005, 105 ( 8 ) : 3058.
3Adams J, PalombeUa V J, SausviUe E A, et al. Proteasome inhibitors: a novel class of potent and effective anti - tumor agents. Cancer Research, 2005, 59:2615.
4Leonard J P, Furman R R,Coleman M,et al. Proteasome inhibition with bortezomib : a new therapeutic strategy for non - Hodgkin's lymphoma. Int Jcancer, 2006,119(5) :971.
5Coy A, Youners A, Mclaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory. B - cell non - Hodgkin' s lymphoma. J Clin Oncol, 2005,23 (4) : 657.
6Orlowski R Z, Voorhees P M,Garcia R A,et al. A phase I trial of bortezomib and pegylated liposomal doxombicin in patients with advanced hematologic maligancies. Blood,2005, 105(8) :3058.
7Nicholas M, Constantine S M, Paul G R, et al. The porteasome inhibitor PS - 341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood ,2006, 101 (6) : 2377.
